SLNO - NASDAQ

Soleno Therapeutics, Inc.

SLNO·NASDAQ

$53.01

+0.038%

HealthcareBiotechnology

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.76B

EPS0.4100

P/E Ratio117.86

Earnings Date08/05/2026

slno

Net Common Stock Issuance

Last Annual Value

137.96M

3-Year CAGR

114%

5-Year CAGR

21%

10-Year CAGR

58%

Adjust for Inflation

Soleno Therapeutics, Inc. Competitors Analysis of Net Common Stock Issuance

SLNO · NASDAQ

Company	Net Common Stock Issuance	CAGR 3Y	CAGR 5Y	CAGR 10Y
Soleno Therapeutics, Inc. NASDAQ:SLNO	137.96M	0.0%	N/A	N/A
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	86.00M	-39.0%	1.7%	0.8%
Dyne Therapeutics, Inc. NASDAQ:DYN	742.61M	142.0%	36.4%	N/A
Celcuity Inc. NASDAQ:CELC	137.85M	112.2%	11.9%	43.5%
Praxis Precision Medicines, Inc. NASDAQ:PRAX	704.26M	97.4%	46.1%	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	2.49M	-79.0%	-20.0%	-14.2%
Apogee Therapeutics, Inc. NASDAQ:APGE	396.49M	7.9%	N/A	N/A
Mirum Pharmaceuticals, Inc. NASDAQ:MIRM	40.14M	-43.0%	42.2%	N/A

Soleno Therapeutics, Inc. Fair Value Envelope

SLNO · NASDAQ

Our analysis suggests that SLNO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $53.01, this represents a potential HIDDEN relative to our calculated worth for Soleno Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $53.01

Related Guides

Blog Categories

Continue your SLNO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.